Cell line · CVCL_0617
MDA-MB-134-VI
Cancer cell line, Homo sapiens. Invasive breast lobular carcinoma. 55 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. MDA-MB-134-VI. Cell lines, record CVCL_0617. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_0617
On this page
Cell line
As Cellosaurus gives it.
- Name
- MDA-MB-134-VI
- Accession
- CVCL_0617
- RRID
- RRID:CVCL_0617
- Synonyms
- MDA-MB-134 VI, MDA MB 134VI, MDA-MB-134VI, MDAMB134VI, MDA-MB-134, MDAMB134, MDA-134, MDA134, MM134, MD Anderson-Metastatic Breast-134-VI
- Species
- Homo sapiens (Human)
- Sex
- Female
- Age at sampling
- 47Y
- Category
- Cancer cell line
- Diseases
- Invasive breast lobular carcinoma (NCIt C7950)
- Derived from
- Pleural effusion (metastatic)
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers55
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RET signaling as a mediator of estrogen receptor positive breast cancer brain metastasis. | Commun Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LOX Inhibition Disrupts a Collagen-Integrin-MYC Axis to Suppress Progression of Invasive Lobular Carcinoma. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2- Metastatic Breast Cancer. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 39464069 | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| ESR1 Fusions Invoke Breast Cancer Subtype-Dependent Enrichment of Ligand-Independent Oncogenic Signatures and Phenotypes. | Endocrinology | 2024 | Its Methods give the RRID and name the line | PubMed | |
| WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer. | J Endocr Soc | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Loss of E-cadherin Induces IGF1R Activation and Reveals a Targetable Pathway in Invasive Lobular Breast Carcinoma. | Mol Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 55
See all 55 papersRelatives0
None in this release.
Cell banks2
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| ATCC | HTB-23 | ATCC | |
| IZSLER | BS TCL 236 | Cellosaurus |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0617
GET https://conductscience.org/api/cell-lines/v1/CVCL_0617/papers?page=2